PMID- 28276253
OWN - NLM
STAT- MEDLINE
DCOM- 20170529
LR  - 20181202
IS  - 1473-4877 (Electronic)
IS  - 0300-7995 (Linking)
VI  - 33
IP  - 5
DP  - 2017 May
TI  - Safety profiles of non-small cell lung cancer patients treated with pemetrexed 
      plus carboplatin: a real-world retrospective, observational, cohort study.
PG  - 931-936
LID - 10.1080/03007995.2017.1297700 [doi]
AB  - OBJECTIVE: Pemetrexed plus carboplatin (PCb) is a frequently used first-line 
      treatment in advanced non-small cell lung cancer (NSCLC). This study examined the 
      characteristics and safety profile of a NSCLC population treated with PCb area 
      under the concentration-time curve 5 (PCb5) or 6 mg/mL*min (PCb6) under 
      real-world conditions. RESEARCH DESIGN AND METHODS: A retrospective, 
      observational, cohort study was conducted, utilizing data from the IMS Oncology 
      US clinic-based, longitudinal, patient-level electronic medical records (EMR), 
      including patients with NSCLC on PCb5 or PCb6 regimens initiated concomitantly on 
      or after the diagnosis of lung cancer during 2004-2014. Patient characteristics 
      and incidence of adverse events (AEs) were described for each cohort. Propensity 
      scores were calculated based on baseline demographic and clinical factors. 
      Propensity score stratification was used to further adjust for cohort 
      differences. RESULTS: In total, 636 NSCLC patients receiving PCb5 (37% aged >/=70 
      years) and 184 patients receiving PCb6 (34% aged >/=70 years) who met the inclusion 
      criteria were identified in the EMR. Patients with more comorbidities were more 
      likely to have received PCb5. Overall incidence rates (IRs) per 100 person-years 
      were similar for neutropenia in both cohorts, were numerically higher for anemia 
      (IR = 43.6 vs 101.0) and thrombocytopenia (IR = 1.5 vs 17.9), and were 
      numerically lower for nausea (IR = 14.4 vs 9.9) in the PCb6 vs PCb5 cohort. 
      Within the PCb6 cohort, the IR per 100 person-years was higher for neutropenia 
      for >/=70 year-old patients (IR = 41.1) compared to <70 year-old patients 
      (IR = 14.5). After propensity score stratification, adjusted IRs showed similar 
      patterns. LIMITATIONS: Limitations included lack of power for AEs other than 
      anemia, given the nature of EMR. CONCLUSIONS: Results from this real-world 
      analysis add to existing evidence from randomized clinical trials about PCb 
      safety profiles in the overall NSCLC population and in elderly patients. These 
      results may guide physicians when making treatment decisions.
FAU - Chen, Lei
AU  - Chen L
AD  - a Eli Lilly and Company , Indianapolis , IN , USA.
FAU - San Antonio, Belen
AU  - San Antonio B
AD  - b Lilly Espana , Madrid , Spain.
FAU - Yan, Yu
AU  - Yan Y
AD  - a Eli Lilly and Company , Indianapolis , IN , USA.
FAU - Chen, Jian
AU  - Chen J
AD  - a Eli Lilly and Company , Indianapolis , IN , USA.
FAU - Goodloe, Robert J
AU  - Goodloe RJ
AD  - a Eli Lilly and Company , Indianapolis , IN , USA.
FAU - John, William J
AU  - John WJ
AD  - a Eli Lilly and Company , Indianapolis , IN , USA.
LA  - eng
PT  - Journal Article
PT  - Observational Study
DEP - 20170309
PL  - England
TA  - Curr Med Res Opin
JT  - Current medical research and opinion
JID - 0351014
RN  - 04Q9AIZ7NO (Pemetrexed)
RN  - BG3F62OND5 (Carboplatin)
SB  - IM
MH  - Aged
MH  - Antineoplastic Combined Chemotherapy Protocols/adverse effects/*therapeutic use
MH  - Carboplatin/administration & dosage
MH  - Carcinoma, Non-Small-Cell Lung/*drug therapy
MH  - Female
MH  - Humans
MH  - Lung Neoplasms/*drug therapy
MH  - Male
MH  - Middle Aged
MH  - Pemetrexed/administration & dosage
MH  - Retrospective Studies
OTO - NOTNLM
OT  - Pemetrexed
OT  - carboplatin
OT  - non-small cell lung cancer
OT  - observational study
OT  - safety
EDAT- 2017/03/10 06:00
MHDA- 2017/05/30 06:00
CRDT- 2017/03/10 06:00
PHST- 2017/03/10 06:00 [pubmed]
PHST- 2017/05/30 06:00 [medline]
PHST- 2017/03/10 06:00 [entrez]
AID - 10.1080/03007995.2017.1297700 [doi]
PST - ppublish
SO  - Curr Med Res Opin. 2017 May;33(5):931-936. doi: 10.1080/03007995.2017.1297700. 
      Epub 2017 Mar 9.